289042-12-2

Basic information

• Product Name: tert-Butyl 6-[(1E)-2-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]ethenyl]-2,2-dimethyl-1,3-dioxane-4-acetate
• Synonyms: 6-[(1E)-2-[4-(4-Fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]ethenyl]-2,2-dimethyl-1,3-dioxane-4-acetic acid 1,1-dimethylethyl ester; Rosuvastatin calcium intermediate R-2; 1,3-Dioxane-4-acetic acid,6-[(1E)-2-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]ethenyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, (4R,6S)-; tert-butyl {(4R,6S)-6-[(E)-2-{4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}ethenyl]-2,2-dimethyl-1,3-dioxan-4-yl}acetate; tert-Butyl 6-[(1E)-2-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl) amino] -5-pyrimidinyl]ethenyl]-2,2-dimethyl-1,3-dioxane-4-acetate; (4R,6S)-6-[(1E)-2-[4-(4-Fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]ethenyl]-2,2-dimethyl-1,3-dioxane-4-acetic Acid 1,1-Dimethylethyl Ester; R-1; R 1; tert-Butyl 6-[(1E)-2-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methyl sulfonyl)amino]-5-pyrimidinyl]ethenyl]-2,2-dimethyl-1,3-dioxane-4-
• CAS NO: 289042-12-2
• Molecular Formula: C₂₉H₄₀FN₃O₆S
• Molecular Weight: 577.7078
• Mol File: 289042-12-2.mol
• Article Data: 30

Chemical Properties

• Boiling Point: 673.348°C at 760 mmHg
• Flash Point: 361.028°C
• Density: 1.211g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.545
• Storage Temp.: Inert atmosphere,2-8°C
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: -0.43±0.10(Predicted)
• CAS DataBase Reference: tert-Butyl 6-[(1E)-2-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]ethenyl]-2,2-dimethyl-1,3-dioxane-4-acetate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 6-[(1E)-2-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]ethenyl]-2,2-dimethyl-1,3-dioxane-4-acetate(289042-12-2)
• EPA Substance Registry System: tert-Butyl 6-[(1E)-2-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]ethenyl]-2,2-dimethyl-1,3-dioxane-4-acetate(289042-12-2)

Safety Data

• Hazardous Substances Data: 289042-12-2(Hazardous Substances Data)

Usage

Description

tert-Butyl 6-[(1E)-2-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]ethenyl]-2,2-dimethyl-1,3-dioxane-4-acetate is a complex organic compound characterized by its white solid appearance. It is a derivative of Rosuvastatin, a well-known HMG-CoA reductase inhibitor, and is specifically identified as Rosuvastatin EP Impurity F.

Uses

Used in Pharmaceutical Industry:
tert-Butyl 6-[(1E)-2-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]ethenyl]-2,2-dimethyl-1,3-dioxane-4-acetate is used as an intermediate in the synthesis of Rosuvastatin (R700500), a HMG-CoA reductase inhibitor. Its role in the pharmaceutical industry is crucial for the development and production of Rosuvastatin, which is a widely prescribed medication for lowering cholesterol levels and reducing the risk of cardiovascular diseases.
Chemical Properties:
tert-Butyl 6-[(1E)-2-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]ethenyl]-2,2-dimethyl-1,3-dioxane-4-acetate is a white solid, which indicates its stability and suitability for use in various chemical reactions and processes within the pharmaceutical industry. Its specific chemical structure and properties contribute to its role as an intermediate in the synthesis of Rosuvastatin, making it a valuable component in the development of this important medication.

Upstream product

• 124752-23-4 tert-butyl 2-[(4R,6S)-6-formyl-2,2-dimethyl-1,3-dioxan-4-yl]acetate 
• 956034-92-7 N-{4-(4-fluorophenyl)-6-isopropyl-5-[(1-methyl-1H-benzo[d]imidazol-2-ylsulfonyl)methyl]pyrimidin-2-yl}-N-methylmethanesulfonamide 
• 853066-73-6 tributyl[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-ylmethyl]phosphonium bromide 
• 894787-92-9 N-(5-bromo-4-(4-fluorophenyl)-6-isopropylpyriinidin-2-yl)-N-methylmethanesulfonamide 
• 153968-96-8 tert-butyl 2-((4R,6S)-2,2-dimethyl-6-vinyl-1,3-dioxan-4-yl)acetate 
• 289042-10-0 N-(5-((diphenylphosphoryl)methyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide 
• 1207460-27-2 tert-butyl 2-((4R,6S)-6-((E)-2-(4-(4'-fluorophenyl)-6-isopropyl-2-(methylamino)pyrimidin-5-yl)vinyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
• 124-63-0 methanesulfonyl chloride 
• 125517-63-7 1,1-Dimethylethyl 6-formyl-2,2-dimethyl-1,3-dioxane-4-acetate 
• 1210451-27-6 N-{4-(4-fluorophenyl)-6-isopropyl-5-[(pyridin-2-ylsulfonyl)methyl]pyrimidin-2-yl}-N-methylmethanesulfonamide 
• 1210451-28-7 N-[5-(3,5-bis-trifluoromethyl-benzenesulfonyl methyl)-4-(4-fluoro-phenyl)-6-isopropyI-pyrimidin-2-yI]-N-methyl-methanesulfonamide 
• 147118-36-3 N-[4-(4-fluorophenyl)-5-(hydroxymethyl)-6-(propan-2-yl)pyrimidin-2-yl]-N-methylmethanesulfonamide 
• 799842-07-2 N-[5-(bromomethyl)-4-(4-fluorophenyl)-6-(propan-2-yl)pyrimidin-2-yl]-N-methylmethanesulfonamide 
• 956034-90-5 N-((5-(1H-benzo[d]imidazol-2-ylthio)methyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methyimethanesulfonamide 

Downstream Products

• 355806-00-7 rosuvastatin tert-butyl ester 
• 355805-96-8 rosuvastatin methylamine salt 
• 894787-93-0 {(4R,6S)-6-[(E)-2-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}vinyl]-2,2-dimethyl-1,3-dioxan-4-yl}acetic acid 
• 1207460-30-7 [(4R,6S)-6-{(E)-2-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl]ethenyl}-2,2-dimethyl-1,3-dioxan-4-yl]acetate 1,1-dimethylethylammonium 
• 287714-41-4 rosuvastatin 
• 1379688-00-2 rosuvastatin ethanolamine 
• 917805-74-4 (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid-2-methylpropan-2-amine 
• 851440-19-2 2-[(4R,6S)-6-[(E)-2-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(isopropyl)pyrimidin-5-yl]vinyl]-2,2-dimethyl-1,3-dioxan-4-yl]acetic acid methyl ester 
• 147118-40-9 (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid methyl ester 
• 1374771-99-9 rosuvastatin arginine salt 
• 1374771-97-7 (3R,55,6E)-7-[4-(4-fluorophenyl)-2-(N-(methyl)methanesulfonamide)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid lysine salt 
• 1714147-49-5 C₂₉H₄₂FN₃O₇S 
• 1094100-06-7 (E)-(3R,5R)-7-[4-(4-fluoro-phenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-3,5-dihydroxy-hept-6-enoic acid 

Relevant articles and documents

Rosuvastatin calcium intermediate compound

The invention belongs to the field of organic chemistry, and discloses a rosuvastatin calcium intermediate compound, a synthesis method thereof and application thereof in preparation of rosuvastatin calcium. The preparation method of the rosuvastatin calcium intermediate compound comprises the following specific steps: (1) reacting a compound III with 5-mercapto-1-phenyltetrazole under the actionof an organic alkali to obtain a compound II; (2) reacting the compound II with an oxidant to obtain a compound I crude product. The prepared rosuvastatin calcium intermediate compound I is novel in structure, short in synthesis route, mild in reaction conditions, high in yield and convenient in after-treatment. The compound I reacts with a rosuvastatin side chain, the reaction conditions are mild, the yield and purity of the product are high, and the method has a good industrial prospect.

Rosuvastatin calcium impurity and method for controlling quality of rosuvastatin calcium

The invention provides a rosuvastatin calcium unknown impurity and a preparation method thereof, and further provides a method for controlling the content of the rosuvastatin calcium impurity. According to the method for controlling the content of the rosuvastatin calcium impurity, the content of the impurity is controlled by controlling the content of a compound shown in formula (RC) in an R1 compound. The invention further provides a method for controlling the quality of rosuvastatin calcium by controlling the content of the rosuvastatin calcium impurity.

Purification method of rosuvastatin calcium intermediate

The invention discloses a purification method of a rosuvastatin calcium intermediate shown as Formula (III) as shown in the specification. The purification method is characterized by comprising the steps of heating and mixing a crude product of the rosuvastatin calcium intermediate shown as Formula (III) and a mixed solution of normal hexane and absolute ethyl alcohol till complete dissolution, and then performing cooling and crystallization. According to the method, the mixed solution of absolute ethyl alcohol and normal hexane serves as a recrystallization solvent for purification of the crude product of the rosuvastatin calcium intermediate shown as Formula (III); the purity of the rosuvastatin calcium intermediate shown as Formula (III) in a prepared product is greater than 99%; the maximum purity is 99.8%; the minimum purity is 99.3%; an effect of removing a cis-isomer is obvious; a cis-isomer content is less than 0.1%; and the purification selectivity is high.